{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:13:10Z","timestamp":1745986390500},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00059-019-4782-y","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T11:27:19Z","timestamp":1549538839000},"page":"45-52","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Akutes Koronarsyndrom"],"prefix":"10.1007","volume":"44","author":[{"given":"U.","family":"Nixdorff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Horstick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"4782_CR1","first-page":"28","volume-title":"Check-Up-Medizin. Pr\u00e4vention von Krankheiten \u2013 Evidenz-basierte Empfehlungen f\u00fcr die Praxis","author":"U Nixdorff","year":"2009","unstructured":"Nixdorff U (2009) Herz-Kreislauf-Check-Up. In: Nixdorff U (Hrsg) Check-Up-Medizin. Pr\u00e4vention von Krankheiten \u2013 Evidenz-basierte Empfehlungen f\u00fcr die Praxis. Thieme, Stuttgart, New York, S 28\u201348"},{"key":"4782_CR2","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et\u00a0al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts), developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart\u00a0J 37:2315\u20132381","journal-title":"Eur Heart J"},{"key":"4782_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1055\/s-0033-1359946","volume":"139","author":"G Horstick","year":"2014","unstructured":"Horstick G (2014) Pr\u00e4vention nach akutem Koronarsyndrom. Dtsch Med Wochenschr 139:S43\u20136","journal-title":"Dtsch Med Wochenschr"},{"key":"4782_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrano C, Collet JP et al (2016) 2015 ESC Guideline for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart\u00a0J 37:267\u2013315","journal-title":"Eur Heart J"},{"key":"4782_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1753-4887.1958.tb00605.x","volume":"16","author":"TR Dawber","year":"1958","unstructured":"Dawber TR, Kannel WB (1958) An epidemiologic study of heart disease: the Framingham study. Nutr Rev 16:1\u20134","journal-title":"Nutr Rev"},{"key":"4782_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937\u2013952","journal-title":"Lancet"},{"key":"4782_CR7","doi-asserted-by":"publisher","first-page":"2H","DOI":"10.1016\/j.amjcard.2006.03.002","volume":"98","author":"M Naghavi","year":"2006","unstructured":"Naghavi M, Falk E, Hecht HS et\u00a0al (2006) From vulnerable plaque to vulnerable patient\u2014part III: executive summary of the screening for heart attack prevention and education (SHAPE) task force report. Am J Cardiol 98:2H\u201315H","journal-title":"Am J Cardiol"},{"key":"4782_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R (1999) Atherosclerosis\u2014an inflammatory disease. N\u00a0Engl J Med 340:115\u2013126","journal-title":"N Engl J Med"},{"key":"4782_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","volume":"106","author":"PM Ridker","year":"2010","unstructured":"Ridker PM, MacFadyen J, Libby P, Glynn RJ (2010) Relation of baseline high-sensitivity C\u2011reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 106:204\u2013209","journal-title":"Am J Cardiol"},{"key":"4782_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T et\u00a0al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N\u00a0Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"key":"4782_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/eurheartj\/ehs076","volume":"33","author":"R Erbel","year":"2012","unstructured":"Erbel R, Budoff M (2012) Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure. Eur Heart\u00a0J 33:1201\u20131217","journal-title":"Eur Heart J"},{"key":"4782_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/med\/9780199656653.003.0006","volume-title":"Imaging in cardiovascular prevention. The ESC Textbook of Preventive Cardiology","author":"U Nixdorff","year":"2015","unstructured":"Nixdorff U, Achenbach S, Bengel F et\u00a0al (2015) Imaging in cardiovascular prevention. The ESC Textbook of Preventive Cardiology. Oxford University Press, Oxford, S\u00a054\u201376"},{"key":"4782_CR13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1056\/NEJMra000650","volume":"345","author":"HV Huikuri","year":"2001","unstructured":"Huikuri HV, Castellanos A, Myerburg RJ (2001) Sudden death due to cardiac arrhythmias. N\u00a0Engl J Med 345:1473\u20131482","journal-title":"N Engl J Med"},{"key":"4782_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ehjci\/jes297","volume":"14","author":"GF Mureddu","year":"2013","unstructured":"Mureddu GF, Brandimarte F, Faggiano P, Rigo F, Nixdorff U (2013) Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice? Eur Heart J Cardiovasc Imaging 14:401\u2013416","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"4782_CR15","first-page":"e584","volume":"122","author":"P Greenland","year":"2010","unstructured":"Greenland P, Alpert JS, Beller GA et\u00a0al (2010) 2010 ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation 122:e584\u2013e636","journal-title":"Circulation"},{"key":"4782_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/hc0302.102575","volume":"105","author":"G Assmann","year":"2002","unstructured":"Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 105:310\u2013315","journal-title":"Circulation"},{"key":"4782_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, D\u2019Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a\u00a0new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157\u2013172","journal-title":"Stat Med"},{"key":"4782_CR18","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H et\u00a0al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart\u00a0J 33:1635\u20131701","journal-title":"Eur Heart J"},{"key":"4782_CR19","first-page":"1","volume":"105","author":"R Erbel","year":"2008","unstructured":"Erbel R, M\u00f6hlenkamp S, Lehmann N et\u00a0al (2008) Kardiovaskul\u00e4re Risikofaktoren und Zeichen subklinischer Atherosklerose. Dtsch \u00c4rztebl 105:1\u20138","journal-title":"Dtsch \u00c4rztebl"},{"key":"4782_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2010.06.030","volume":"56","author":"R Erbel","year":"2010","unstructured":"Erbel R, M\u00f6hlenkamp S, Moebus S et\u00a0al (2010) Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall Study. J\u00a0Am Coll Cardiol 56:1397\u20131406","journal-title":"J Am Coll Cardiol"},{"key":"4782_CR21","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1177\/2047487318798058","volume":"25","author":"K Osawa","year":"2018","unstructured":"Osawa K, Trejo MEP, Nakanishi R (2018) Coronary artery calcium and carotid artery intima-media thickness for the prediction of stroke and benefit from statins. Eur J Prev Cardiol 25:1980\u20131987","journal-title":"Eur J Prev Cardiol"},{"key":"4782_CR22","first-page":"1535","volume":"375","author":"The Lp-PLA2 Studies Collaboration","year":"2010","unstructured":"The Lp-PLA2 Studies Collaboration (2010) Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375:1535\u20131544","journal-title":"Lancet"},{"key":"4782_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32818-6","author":"U N\u00e4slund","year":"2018","unstructured":"N\u00e4slund U, Ng N, Lundgren A et al (2018) Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a\u00a0pragmatic, open-label, randomised controlled trial. Lancet. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32818-6","journal-title":"Lancet"},{"key":"4782_CR24","unstructured":"Lechner K, McKenzie AL, von Schacky C et\u00a0al Paradigm shift in cardiovascular prevention: causal and not symptomatic therapy. A review. JAMA Intern Med. (submitted)"},{"key":"4782_CR25","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1161\/CIRCULATIONAHA.107.738732","volume":"117","author":"D Mozaffarian","year":"2008","unstructured":"Mozaffarian D, Wilson PW, Kannel WB (2008) Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 117:3031\u20133038","journal-title":"Circulation"},{"key":"4782_CR26","first-page":"49","volume-title":"Clinical management of coronary heart disease risk factors. Modification of lifestyle: stopping smoking. Pocket guide to: prevention of coronary heart disease","author":"U Nixdorff","year":"2009","unstructured":"Nixdorff U (2009) Clinical management of coronary heart disease risk factors. Modification of lifestyle: stopping smoking. Pocket guide to: prevention of coronary heart disease. Thomson Reuters, M\u00fcnster, S\u00a049\u201352 (International Task Force for Prevention of Coronary Heart Disease, International Atherosclerosis Society)"},{"key":"4782_CR27","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(18)31812-9","volume":"392","author":"M Dehghan","year":"2018","unstructured":"Dehghan M, Mente A, Rangarajan S et\u00a0al (2018) Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a\u00a0prospective cohort study. Lancet 392:2288\u20132297","journal-title":"Lancet"},{"key":"4782_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering E et\u00a0al (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart\u00a0J 39:3021\u20133104","journal-title":"Eur Heart J"},{"key":"4782_CR29","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G et\u00a0al (2016) 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart\u00a0J 37:2999\u20133058","journal-title":"Eur Heart J"},{"key":"4782_CR30","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD et al (2013) ESC Guideline on diabetes, pre-diabetes, and cardiovascular disease developed in collaboration with the EASD. Eur Heart\u00a0J 34:3035\u20133087","journal-title":"Eur Heart J"},{"key":"4782_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Steering Committee of the Physicians\u2019 Health Study Research Group","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group (1989) Final report on the Aspirin component of the ongoing Physicians\u2019 Health Study. N\u00a0Engl J Med 321:129\u2013135","journal-title":"N Engl J Med"},{"key":"4782_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Woods RL, Nelson MR et al (2018) Effect of Aspirin on disability-free survival in the healthy elderly. N\u00a0Engl J Med 379:1499\u20131508","journal-title":"N Engl J Med"},{"key":"4782_CR33","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R et al (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 392:1036\u20131046","journal-title":"Lancet"},{"key":"4782_CR34","unstructured":"Leitlinie zur Rehabilitation von Patienten mit Herzkreislauferkrankungen (LL-KardReha) Deutschland \u2013 \u00d6sterreich \u2013 Schweiz 2019; in Bearbeitung durch Deutsche Gesellschaft f\u00fcr Pr\u00e4vention und Rehabilitation von Herz-Kreislauferkrankungen (DGPR)."},{"key":"4782_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J et al (2018) Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391:205\u2013218","journal-title":"Lancet"},{"key":"4782_CR36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","volume":"367","author":"LH Opie","year":"2006","unstructured":"Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA (2006) Controversies in ventricular remodelling. Lancet 367:356\u2013367","journal-title":"Lancet"},{"key":"4782_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0167-5273(93)90134-3","volume":"41","author":"U Nixdorff","year":"1993","unstructured":"Nixdorff U, Erbel R, Pop T et al (1993) Long-term follow-up of global and regional left ventricular function by two-dimensional echocardiography after thrombolytic therapy in acute myocardial infarction. Int J Cardiol 41:31\u201347","journal-title":"Int J Cardiol"},{"key":"4782_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00108-017-0239-7","volume":"58","author":"K Werdan","year":"2017","unstructured":"Werdan K, Baldus S, Frey N et\u00a0al (2017) Klug entscheiden \u2013 Empfehlungen in der Kardiologie. Internist 58:556\u2013567","journal-title":"Internist"},{"key":"4782_CR39","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et\u00a0al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N\u00a0Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"4782_CR40","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et\u00a0al (2017) Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N\u00a0Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4782-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T14:56:08Z","timestamp":1580741768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4782-y"}},"subtitle":["Pr\u00e4vention"],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4782"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4782-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"22 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Nixdorff, G.\u00a0Horstick und A.\u00a0Schlitt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}